VKTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Viking Therapeutics (VKTX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company is positioned to benefit from the surging obesity treatment market, with its VK2735 injectable in phase 3 trials and strong growth potential in a $100 billion market by 2030. Despite negative financial performance, the stock's technical indicators, bullish sentiment, and potential market catalysts make it a compelling long-term investment opportunity.
The stock is showing bullish momentum with MACD above 0 and positively contracting, RSI in the neutral zone at 64.851, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels, with a pivot at 34.49 and resistance at 36.32, indicating room for further upside.
VK2735 injectable in phase 3 trials targeting the obesity market, projected to reach $100 billion by
Positive news sentiment highlighting the company's strong market positioning and clinical trial progress.
Recent investor conferences aimed at enhancing visibility and attracting investors.
Financial performance remains weak with negative net income and EPS despite YoY improvement.
No significant hedge fund or insider trading trends, indicating a lack of strong institutional support.
In 2025/Q4, revenue remained at 0 with no growth. Net income improved YoY but remains negative at -$157.66 million. EPS also improved YoY but is still negative at -1.38. Gross margin remains at 0, indicating no revenue generation yet.
Morgan Stanley analyst Michael Ulz maintains an Overweight rating on VKTX but slightly lowered the price target from $102 to $99, reflecting continued confidence in the stock's long-term potential.
